Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Net Letter
87 (
2
); 321-321
doi:
10.25259/IJDVL_687_19
CROSSMARK LOGO Buy Reprints
PDF

Atenolol use for infantile hemangiomas

Department of Dermatology, National Children Health Institute, Breña, Lima, Peru
Department of Dermatology, Dos de Mayo National Hospital, Lima, Peru
Department of Dermatology, Carlos Alberto Seguin Escobedo National Hospital, Arequipa, Peru
Corresponding author: Dr. Consuelo Apagüeño, Department of Dermatology, National Children Health Institute, Av.Brasil 600, Breña 15083, Lima, Peru. consuelodejesus111@hotmail.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Ballona R, Velásquez F, Kikushima I, Zevallos JP, Nuñez J, Apagüeño C. Atenolol use for infantile hemangiomas. Indian J Dermatol Venereol Leprol. Indian J Dermatol Venereol Leprol 2021;87:321-321.

Sir,

Infantile hemangiomas are the most common, benign, vascular tumor of childhood. Although most infantile hemangiomas resolve spontaneously, approximately 10% of lesions may present with complications such as functional impairment of a vital organ or disfigurement.1 Propranolol is the first-line treatment for infantile hemangiomas requiring systemic intervention; however, 2.1% of treated patients reported side effects such as sleep disturbances, bronchial hyperreactivity and agitation.2,3 Previous reports suggest that atenolol, a hydrophilic beta-1 selective blocker, is an effective alternative for patients with contraindications to propranolol or who develop certain side effects associated with β2-adrenergic receptor blockades like hypoglycemia or bronchial hyperreactivity. Atenolol has been shown to have the same effectiveness as propranolol for infantile hemangioma with fewer side effects.4-6

Herein, we report an observational, prospective, uncontrolled, cross-sectional study performed at the Department of Dermatology of the National Children Health Institute, Breña, Lima to evaluate the clinical improvement of infantile hemangiomas that were treated with atenolol. Inclusion criteria were proliferative hemangiomas and infantile hemangiomas with a high risk of functional impairment, disfigurement or ulceration. Infants with neurological, respiratory or renal involvement were excluded. Informed consent was obtained from parents for the use of atenolol. A complete medical and family history was obtained. Complete physical examination and baseline electrocardiogram were performed.

Patients were prescribed atenolol 5 mg/mL syrup starting at 1 mg/kg/day to be taken once a day in the morning and within 20 min of finishing breastfeeding; after 7 days the dose was increased to 2 mg/kg/day and only patient 4 required a dose escalation to 3 mg/kg/day. The atenolol dose was adjusted based on the patients’ weight monthly. At each visit, blood pressure and heart rate were monitored and parents were asked to look for sleep disturbances, agitation, lethargy, bronchospasm, constipation, diarrhea, vomiting, poor appetite, cool or sweaty extremities in the infants.

Changes in texture, color and size of the lesions were clinically evaluated, photographed and digitally recorded. The hemangioma activity score was used and the percentage of improvement was calculated at 4 and 9 months of age; however, for patient 1 this evaluation was completed after 6 and 9 months of age. The clinical improvement observed was considered very good if hemangioma regression was 90% and good if over 70%.

Four infant patients with infantile hemangiomas were treated with atenolol with the average age at the start of treatment being 2.5 months [Table 1]. Patient 1 had a large hemangioma on the upper eyelid [Figure 1a] that restricted the eye-opening and caused amblyopia; a magnetic resonance image showing presence of only soft tissues; patient 2 presented with a preauricular hemangioma that covered the external auditory canal and had parotid involvement. Patient 3 had an extensive infantile hemangioma located on the midfrontal aspect of the scalp (thus ruling out cranial dysraphism). Patient 4 had a very large hemangioma that involved the lower lip, chin and right jawline area [Figure 2a]. Scalp, brain and cervical magnetic resonance imaging scans and an echocardiogram were performed that ruled out subglottic hemangioma as well as posterior fossa anomalies, hemangioma, as well as arterial, cardiac and eye anomalies that may occur in various associated syndromes.

Figure 1a:: Patient 1, mixed hemangioma in the upper eyelid
Figure 1b:: At 6 months of age
Figure 1c:: Residual fibro adipose tissue at 9 months of age
Figure 2a:: Patient 4, extensive segmental hemangioma

The clinical response in the above cases treated with atenolol were observed and documented [Figures 1b, c and 2b, c]. Atenolol was administered at 2–3 mg/kg/day based on the severity of the lesions as reported in few previous studies.1,5 Clinical improvement was observed right from the first month of starting the treatment with changes in the color, softening and decrease in size. The average duration by which atenolol could be discontinued was 7 months when the hemangioma activity score showed a regression of over 70%. Atenolol was administered till the infants reached 9 months of age to reduce the risk of rebound growth which can occur if therapy is discontinued before this age. Blood pressure, heart rate and vitals were not affected and no systemic side effects were reported. All children were followed up to 12 months of age and no child had rebound growth of the hemangiomas [Table 1].

All our cases administered with atenolol had results similar to the other published studies without any significant side effects.4-6 Previous publications on the use of atenolol for infantile hemangiomas report this medication as a good alternative to propranolol, only requiring an evaluation from a cardiologist and a baseline electrocardiogram and no other laboratory tests. Like with propranolol, the dosage will depend on the response to treatment which is usually determined by the complexity of the hemangioma and the age of the patient. Our literature review also revealed that atenolol has fewer side effects like bronchial hyperreactivity and sleep disturbance when compared to propranolol; hence, the safety profile is advantageous.4-6 The once-daily dose is also another advantage since it leads to better treatment adherence.2 More importantly, atenolol has also been reported to have adequate efficacy in the treatment of complicated infantile hemangiomas.6

Figure 2b:: At 4 months of age
Figure 2c:: Residual telangiectasias at 9 months of age
Table 1:: Clinical evolution of infantile hemangioma in patients treated with atenolol
Patient Sex Location Type of hemangioma Size (mm) Indication Dose (mg/kg/day) Age of onset treatment (months) Improvement percentage at 4th month of age (%) Improvement percentage at 9th month of age (%) Treatment time (months) Residual lesion Adverse events
1 Girl child Eyelid Mixed 75×40 Functional 2 4 60* 90 7 Fibrofatty tissue None
2 Girl child Preauricular Mixed 40×25 Functional 2 2 67 100 7 None None
3 Girl child Scalp Mixed 50×45 Disfigurement 2 2 77 82 7 None None
4 Girl child Face Superficial 250×100 Functional/ulceration 3 2 54 70 8 Telangiectasias None
Improvement percentage at 6 months

We report our experience in the management of four cases of infantile hemangiomas in whom early treatment with atenolol at a dose of 2–3 mg/kg/day during the proliferative phase was initiated. It is also proved to be a safe intervention as none of the patients presented with any side effects, and also had better adherence. Prospective studies with a higher number of patients are needed to further investigate the efficacy and safety of this intervention.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , , , . Atenolol treatment for severe Infantile Hemangiomas: A single-center prospective study. J Eur Acad Dermatol Venereol. 2018;32:e117-9.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics2019;. ;143(1)
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Intolerable side effects during propranolol therapy for infantile hemangioma: Frequency, risk factors and management. Sci Rep. 2018;8(1):4264.
    [CrossRef] [PubMed] [Google Scholar]
  4. , . Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas. PediatrDermatol. 2019;36(4):556-557.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , . Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: A retrospective noninferiority study. Pediatr Dermatol. 2017;34(4):413-421.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , . Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. Australas J Dermatol. 2019;60(3):181-185.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
799

PDF downloads
350
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections